References
- Fukuoka M, Yano S, Giaccone G, et al. Multi-institution-al randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237–46.
- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefi-tinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149–58.
- Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004; 22: 330–53.
- Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefi-tinib. J Clin Oncol 2005; 23: 165–74.
- Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556–68.
- Lynch TJ, Bell DW, Sordella R, et al. Activating muta-tions in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55.
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.
- Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354–62.
- Hanna N, Shepherd FA, FosseIla FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
- Shepherd FA, Pereira J, Ciuleanu TE, et al. A random-ized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st-line or 2nd-line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Onc 2004; 22: a7022.
- Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103–09.
- Katakami N, Okazaki M, Kinose D, et al. A retrospec-tive analysis of the outcome of patients (pts) with advanced recurrent adenocarcinoma of the lung who have received gefi-tinib after treatment of platinum-base regimen. Proc Am Soc Clin Oncol 2003; 22: 666a.
- Wong NS, Lim ST, Lim WT, et al. ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc Am Soc Clin Oncol 2003; 22: 694a.
- Herbst RS, Kim ES. Novel therapeutic options for non-small-cell lung cancer (second-line and subsequent therapy). Educational book of Am Soc Clin Oncol 2003; 22: 654–66.
- Chou TY, Chiu CH, Li LH, et al. Mutation in the tyro-sine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small-cell lung cancer. Clin Cancer Res 2005 (in print)
- Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor muta- tion in non-small-cell lung cancer patients treated with gefi-tinib. J Clin Oncol 2005; 23: 2493–501.
- Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513–20.
- Baselga J. The science of EGFR inhibition: a roadmap to improved outcomes? Signal 2004; 5: 4–8.